GlassScriptPhysician profile
Suzan Khoromi
NPI 1588803340
$31,202.45
in general payments reported to CMS, 2019-2025
20 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $4,311 · 2021: $391 · 2022: $173 · 2023: $335 · 2024: $522 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979 · Consulting Fee: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.23 |
| Consulting Fee | $245.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28,510.55 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Novartis Pharmaceuticals Corporation | $754.41 | 2019-2025 | |
| Abbvie INC. | $308.43 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $275.88 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $220.69 | 2019-2020 | |
| Allergan, INC. | $185.65 | 2019-2020 | |
| Genentech, INC. | $159.84 | 2019-2021 | |
| Horizon Therapeutics Plc | $142.04 | 2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $102.29 | 2020 | |
| Lundbeck LLC | $88.71 | 2025 | Vyepti |
| Biocodex, INC. | $81.57 | 2021 | |
| Amgen INC. | $75.48 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $70.15 | 2019 | |
| Pfizer INC. | $63.38 | 2024-2025 | |
| Axsome Therapeutics, INC. | $61.56 | 2025 | Symbravo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.34 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $22.01 | 2020 | |
| Csl Behring | $17.63 | 2019 | |
| Eisai INC. | $15.91 | 2019 | |
| Genentech USA, INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan Khoromi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.